Saloni Subha ( Intern Journalist ) The Serum Institute of India has begun phase 2/3 of the trial of the Oxford University-Astra-Zeneca Covid-19 vaccine candidate, covishield, to check it’s efficiency at Bharti Vidyapeeth Deemed University Medical College and Hospital at Pune.
SII is the world’s largest producer of the vaccine by the number of doses produced and sold globally. It has entered a manufacturing partnership with AstraZeneca to produce the vaccine.
As per the clinical Trials Registry of India, 17 sites are selected to conduct the phase 2/3 trials, observer-blind, randomized, controlled study to check the safety and immune response of the vaccine candidate among healthy Indian adults.
The trials will be conducted at AIIMs Delhi, BJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Science ( RMRIMS) in Patna, post-Graduate Institute of Medical Education and Research in Chandigarh, AIIMs Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore, among others.
About Post Author
